BACE1 and Alzheimer disease: In the advanced glycation end products induced AD model in vitro and in vivo, 1,8‐cineole can reduce abnormal tau protein phosphorylation at thr205, thr181, and ser396 by inhibiting BACE‐1 activity, downregulating GSK‐3β activity, and reducing Aβ production.151